Open-Source SDC Tools vs EHR-Native Forms for Oncology Workflows

Oncology services choosing how to capture patient-reported outcomes, toxicity grading, and staging information face a recurring decision in 2026: stand up an open-source SDC tool like LHC-Forms outside the EHR, or stay inside the EHR with its native form layer. The choice matters because oncology data has to flow into the cancer registry, into research data warehouses, and into patient-facing portals, often all three. For related FHIR tooling reviews, the broader reference walks through adjacent product comparisons.

What Each Approach Optimizes For

Open-source SDC tools optimize for portability and standards fidelity. LHC-Forms, Form.io with FHIR plugins, and a handful of similar tools render FHIR Questionnaires natively and produce QuestionnaireResponses that any FHIR consumer can read. Oncology programs adopt this path when they have a research arm that needs the data in a portable form or when the cancer center participates in multi-site trials.

EHR-native forms optimize for clinical workflow integration. The form lives inside Epic, Cerner, or whichever EHR the cancer center runs, with no external infrastructure and no separate authentication layer. Clinicians find this easier on day one. The trade-off is that the captured data is shaped by the EHR's internal model, which makes downstream submission to the cancer registry, to a trial sponsor, or to a third-party patient portal a separate engineering effort.

Where the Two Diverge for Oncology Specifically

Three oncology-specific scenarios make the trade-off concrete. Adaptive PROMIS testing runs better in an open-source SDC tool because the FHIRPath expression layer handles the score-driven next-item logic in a portable way. EHR-native forms can do it, but the implementation tends to be vendor-specific and harder to validate. Toxicity-grading workflows favor EHR-native when the grading drives an immediate clinical alert, since the form already sits inside the clinical event stream. Trial-aligned capture favors open-source because the trial sponsor's CRF specification is typically defined in FHIR Questionnaire form, and the same definition can be used across sites.

Cancer centers running multi-site trials get the most value from open-source SDC because of the cross-site reuse argument. Single-site community cancer programs without a research arm get more value from EHR-native because the integration cost is lower. The cardiology cornerstone walks through the broader selection framework, and the cancer center PRO walkthrough gets into the engine-by-engine comparison.

How to Pick in Practice in 2026

The deciding question is where oncology data has to flow over the next three years. If the answer is "into the EHR chart and nowhere else," EHR-native is the lower-friction path. If the answer involves the cancer registry, a clinical trial sponsor, a patient-facing app, or a research data warehouse, the open-source SDC path pays back the extra infrastructure investment.

Most cancer centers in 2026 land on a hybrid. Operational forms stay in the EHR; research-aligned PRO capture moves to an open-source SDC tool that talks to the EHR via the FHIR API. That split usually outperforms either pure approach, as long as the team is honest about what runs where.

Most cancer centers in 2026 settle the question by mapping out where the data goes, then picking the approach that minimizes friction along the most-traveled paths. The right answer is rarely all-or-nothing; it is usually a clear split between operational forms in the EHR and research-aligned PRO capture in an open-source SDC layer.

The hybrid pattern works because the two approaches optimize for different things, and a single oncology service rarely needs to optimize the entire data flow the same way. The team that maps each data destination and picks the right tool for each path ends up with a more defensible architecture than one that forces a single choice across the board.